Varma Mutual Pension Insurance Co Buys 1,000 Shares of argenex SE $ARGX

Varma Mutual Pension Insurance Co raised its position in argenex SE (NASDAQ:ARGX) by 33.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,000 shares of the company’s stock after buying an additional 1,000 shares during the period. Varma Mutual Pension Insurance Co’s holdings in argenex were worth $2,950,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Adage Capital Partners GP L.L.C. raised its stake in shares of argenex by 114.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after acquiring an additional 158,476 shares during the last quarter. Franklin Resources Inc. boosted its stake in argenex by 103.9% in the second quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock worth $154,233,000 after purchasing an additional 142,606 shares in the last quarter. Jennison Associates LLC boosted its stake in argenex by 6.1% in the second quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock worth $145,879,000 after purchasing an additional 15,186 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in shares of argenex by 14.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock worth $162,160,000 after purchasing an additional 26,343 shares during the last quarter. Finally, Orbimed Advisors LLC increased its stake in shares of argenex by 0.6% in the second quarter. Orbimed Advisors LLC now owns 208,000 shares of the company’s stock valued at $114,654,000 after buying an additional 1,300 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the topic of a number of research analyst reports. Wells Fargo & Company increased their price objective on shares of argenex from $1,264.00 to $1,317.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Robert W. Baird lowered shares of argenex from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 18th. Stifel Nicolaus raised their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Citigroup dropped their price objective on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating for the company in a research report on Thursday, January 8th. Finally, DZ Bank upgraded argenex to a “strong-buy” rating in a research report on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $986.78.

argenex Stock Down 1.4%

ARGX stock opened at $821.96 on Friday. argenex SE has a twelve month low of $510.05 and a twelve month high of $934.62. The company has a market cap of $50.86 billion, a P/E ratio of 35.29, a price-to-earnings-growth ratio of 0.72 and a beta of 0.37. The business’s fifty day moving average is $836.13 and its 200-day moving average is $799.14.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.